IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i4p2392-d753186.html
   My bibliography  Save this article

Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants

Author

Listed:
  • Rachel Siqueira de Queiroz Simões

    (Institute of Technology in Immunobiologicals, Bio-Manguinhos, Oswaldo Cruz Foundation, Fiocruz, Avenida Brasil, 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil
    Microbiology Division, Faculty of Sciences, University of Burgos, 09001 Burgos, Spain
    Research Centre for Emerging Pathogens and Global Health, University of Burgos, 09001 Burgos, Spain)

  • David Rodríguez-Lázaro

    (Microbiology Division, Faculty of Sciences, University of Burgos, 09001 Burgos, Spain
    Research Centre for Emerging Pathogens and Global Health, University of Burgos, 09001 Burgos, Spain)

Abstract

Several coronaviruses (CoVs) have been identified as human pathogens, including the α-CoVs strains HCoV-229E and HCoV-NL63 and the β-CoVs strains HCoV-HKU1 and HCoV-OC43. SARS-CoV, MERS-CoV, and SARS-CoV-2 are also classified as β-coronavirus. New SARS-CoV-2 spike genomic variants are responsible for human-to-human and interspecies transmissibility, consequences of adaptations of strains from animals to humans. The receptor-binding domain (RBD) of SARS-CoV-2 binds to receptor ACE2 in humans and animal species with high affinity, suggesting there have been adaptive genomic variants. New genomic variants including the incorporation, replacement, or deletion of the amino acids at a variety of positions in the S protein have been documented and are associated with the emergence of new strains adapted to different hosts. Interactions between mutated residues and RBD have been demonstrated by structural modelling of variants including D614G, B.1.1.7, B1.351, P.1, P2; other genomic variants allow escape from antibodies generated by vaccines. Epidemiological and molecular tools are being used for real-time tracking of pathogen evolution and particularly new SARS-CoV-2 variants. COVID-19 vaccines obtained from classical and next-generation vaccine production platforms have entered clinicals trials. Biotechnology strategies of the first generation (attenuated and inactivated virus–CoronaVac, CoVaxin; BBIBP-CorV), second generation (replicating-incompetent vector vaccines–ChAdOx-1; Ad5-nCoV; Sputnik V; JNJ-78436735 vaccine-replicating-competent vector, protein subunits, virus-like particles–NVX-CoV2373 vaccine), and third generation (nucleic-acid vaccines–INO-4800 (DNA); mRNA-1273 and BNT 162b (RNA vaccines) have been used. Additionally, dendritic cells (LV-SMENP-DC) and artificial antigen-presenting (aAPC) cells modified with lentiviral vector have also been developed to inhibit viral activity. Recombinant vaccines against COVID-19 are continuously being applied, and new clinical trials have been tested by interchangeability studies of viral vaccines developed by classical and next-generation platforms.

Suggested Citation

  • Rachel Siqueira de Queiroz Simões & David Rodríguez-Lázaro, 2022. "Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants," IJERPH, MDPI, vol. 19(4), pages 1-24, February.
  • Handle: RePEc:gam:jijerp:v:19:y:2022:i:4:p:2392-:d:753186
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/4/2392/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/19/4/2392/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Ewen Callaway, 2020. "Coronavirus vaccine trials have delivered their first results — but their promise is still unclear," Nature, Nature, vol. 581(7809), pages 363-364, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Stipic, Dorian & Bradac, Mislav & Lipic, Tomislav & Podobnik, Boris, 2021. "Effects of quarantine disobedience and mobility restrictions on COVID-19 pandemic waves in dynamical networks," Chaos, Solitons & Fractals, Elsevier, vol. 150(C).

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:4:p:2392-:d:753186. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.